Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 6.15%
As of Friday, October 09, Spyre Therapeutics, Inc.’s SYRE share price has surged by 6.15%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Commentary & Analysis
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Down 8.40%
As of Tuesday, October 06, Spyre Therapeutics, Inc.’s SYRE share price has dipped by 8.40%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Down 12.04%
As of Tuesday, October 06, Spyre Therapeutics, Inc.’s SYRE share price has dipped by 12.04%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 5.06%
As of Thursday, October 01, Spyre Therapeutics, Inc.’s SYRE share price has surged by 5.06%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Spyre Therapeutics, Inc.’s (SYRE) Stock Is Up 9.51%
As of Wednesday, September 30, Spyre Therapeutics, Inc.’s SYRE share price has surged by 9.51%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | SYRE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,027.5 | $237.5 | 75% |
|
| Shares Out (Mil) | 84.7 | 53.9 | 59% |
|
| Institutional Ownership | 94.9% | 93.1% | 66% |
|
| Float (Mil) | 77.6 | 41.4 | 56% |
|
| Beta | 3.03 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 1,798 | 628 | 79% |
|
| Price Change (52-week) |
305.8% | 49.0% | 99% |
|
| Growth | SYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.4% | na |
|
| Net Income (5yr) | (13.9%) | (10.2%) | 26% |
|
| EPS (5yr) | 44.6% | 15.7% | 91 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 14 | 14 | 14 | |
| Current EPS | ($0.822) | ($2.847) | ($3.522) | |
| Month Ago EPS | ($0.833) | ($2.883) | ($3.523) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.725) | ($2.947) | ($3.128) | |
| Year/Year Chg | 125.2% | 44.2% | 107.1% | |
| Financials | SYRE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($179) | ($44) | 7% |
|
| EPS (TTM) | ($2.010) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($209) | ($33) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $80 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $8,202 | $174 | 70% |
|
| Valuation | SYRE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.92 | 2.27 | 88% |
|
| P/E | na | 19.7 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SYRE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (20.9%) | (47.7%) | 20% |
|
| ROE | (28.5%) | (55.0%) | 20% |
|
| Liabilities to Assets | 6.1% | 29.4% | 3% |
|
| F-Score | 2 | 2 | 7% |
|
Spyre Therapeutics, Inc. did not pass any screens on 10/12/2026.
